The FDA has also issued a new warning about a long-acting osteoporosis drug called Reclast. This medication is injected once a year to strengthen bones and prevent fractures. The FDA has received two dozen reports of serious kidney problems associated with Reclast. The agency advises against using this drug in patients with kidney problems and warns doctors to make sure that patients are properly hydrated before getting the infusion. Kidney function should be monitored both before and after giving Reclast.
The People's Perspective on Medicine